TIDieR-Children and Adolescents (TIDieR-C) Fillable Checklist

Original TIDieR Item	Pediatric Considerations	Location reported
1. Brief name: Provide the name or a phrase that describes the intervention	None	
2. Why: Describe any rationale, theory, or goal of the elements essential to the intervention	**2.1** Provide a justification for the experimental and comparator interventions in children/adolescents. **2.2** Describe any essential pediatric elements to the experimental and comparator interventions. **2.3*** Provide a rationale for adapting interventions used in other populations for the present trial.	
3. What (materials): Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in the training of intervention providers. Provide information on where the materials can be accessed (e.g. online appendix, URL).	**3.1** Describe if materials were appropriate for the size and/or developmental stage of children/adolescents.	
4. What (procedures): Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities.	**4.1*** Describe any support and methods employed to reduce pain, anxiety, fear, or stress in children/adolescents. **4.2*** Describe any safety measures placed to protect children/ adolescents/caregivers associated with the intervention.	
5. Who provided: For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific training given.	**5.1*** Describe if a support person was needed in delivering experimental/comparator interventions to children/adolescents.	
6. How: Describe the modes of delivery (e.g., face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group.	**6.1*** Describe how the mode of delivery was developmentally appropriate for children/adolescents.	
7. Where: Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features.	**7.1** Describe the rationale for the specific location that was chosen for delivery of the experimental/comparator intervention to facilitate inclusion and safety of children/adolescents.	
8. When and how much: Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose.	**8.1** Specify how the experimental and comparator intervention dose, dose interval and duration were determined (e.g., weight, body surface area, safety), and if applicable, specify the route (PO, IV, tube), of administration. **8.2*** Describe how the formulation and palatability of the pharmacological intervention was appropriate for the trial population. **8.3*** Describe any modifications to dosing as children/adolescents aged and grew during the trial period.	
9. Tailoring: If the intervention was planned to be personalized, titrated or adapted, then describe what, why, when, and how.	**9.1** Describe any signs or symptoms considering the developmental stage of the child/adolescent that would trigger an adaptation/titration.	

Original TIDieR Item	Pediatric Considerations	Location reported
10. Modifications: If the intervention was modified during the course of the study, describe the changes (what, why, when, and how).	None.	
11. How well (planned): If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them.	None.	
12. How well (actual): If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.	None.	

*Report pediatric consideration if applicable; otherwise, clearly state that it is not applicable, and if relevant, provide an explanation.

Citation: Goren K, Lai VKW, Baba A, et al. Transparent Reporting of Pediatric Clinical Trial Interventions: TIDieR-Children and Adolescents. Pediatrics. 2025;156(5):e2025072867